



**Mindray Medical International Limited
Acquisition of Datascope PMB Business
March 2008**



MINDRAY

Disclaimer

This material contains forward-looking statements including those with respect to Mindray's planned acquisition, including expectations that the transaction will be accretive, the planned financing of the transaction, the timing and anticipated synergies to the combined business and to Datascope's and Mindray's customers. These and the other forward-looking statements contained in this press release may not occur and actual results may differ materially. The transaction may not close when expected or at all and is subject to receipt of governmental approval and other customary closing conditions. Among other risks Mindray may be unable to build a competitive presence in the United States and Europe, to tailor products to satisfy consumer demands and enhance product functionality, to maintain or retain Datascope's existing product lines and personnel. The financial and other success of the proposed transaction is dependent on the outlook regarding market share in specific product markets and geographies, outlook regarding drivers, developments and trends affecting the combined business's worldwide markets, new product development and commercial launch dates. These statements are based on information available at the time they are made and are subject to a number of risks and uncertainties. Actual results could differ materially from those anticipated by these forward-looking statements as a result of a number of factors, some of which may be beyond the company's control. Factors that affect Mindray's business operations and product development, as well as a further list and description of risks and uncertainties associated with Mindray's business, are discussed in its reports filed with the Securities and Exchange Commission, including its most recent annual report on Form 20-F. Mindray disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Transaction Overview

Mindray is pleased to announce the execution of a definitive agreement with Datascope to acquire its Patient Monitoring business, to be integrated into the global strategy of Mindray

Assets Included:	Patient Monitoring business (“PMB”) Mahwah manufacturing facility Trademarks Global Technology Services business associated with Patient Monitoring business Direct sales force Intellectual property Netherlands warehouse facility
Purchase Consideration^{1,2}:	\$240 million (implied CY 07 revenue multiple of 1.5x)
Timing:	Deal expected to close in Q2 2008, subject to customary closing conditions and regulatory approvals
Financing:	Will be financed by cash on balance sheet and debt
Non-GAAP EPS Impact:	Expected to be accretive in 09

Note:

- 1 Based on reported CY07 revenue for patient monitoring business of \$161.3mm
- 2 \$202 million in cash and \$38m in account receivables to be retained by Datascope

Transaction Highlights

Global Footprint

- Broadens Mindray international presence and significantly increases US operational footprint
- Increases MR total 07 revenue base by ~53%

US Infrastructure & Direct Distribution

- Provides immediate direct sales and service capabilities in US
- Enhances R&D capabilities for the combined entity
- Creates cross-selling opportunities for MR's product lines

Strong Brand

- The Mindray/PMB combination will bring together two leading brands in patient monitoring
- Use of the Datascope brand through 2015

Manufacturing and R&D Outsourcing Savings

- Significant opportunity to improve gross margins on DSCP stand-alone monitors
- Enhanced product offerings with access to China-based R&D capabilities

Significant Operating Synergies

- Mindray expects to achieve approximately \$30mm of run-rate synergies in the areas of manufacturing, SG&A and R&D within 3 years

Datascope Patient Monitoring Business




- Division of Datascope, a publicly traded company on NASDAQ (DSCP)
- Headquartered in Mahwah, NJ
- ~440 employees worldwide
- Provides broad array of patient monitoring products
- Three major product lines
 - Standalone Monitors
 - Central Monitoring Systems
 - Anesthesia Delivery Systems
- CY07 revenue of \$161.3mm

Transaction Creates A Global Player...



... Creating the #3 Global Leader in Patient Monitoring



Source: 2007 Frost & Sullivan research

A Perfect Fit of Complementary Assets...




- Leading market position in China
- Established and rapidly growing presence outside of China
 - Sales in more than 140 countries
 - More than 1,200 international distributors
- Revenue growth of 47% and net income growth of 64% in 2007
- World-class R&D platform with more than 1,000 R&D engineers
- More than 3,700 employees worldwide



- Strong brand name in US patient monitoring market
- Leading share in specific sub-segments of US Patient Monitoring Market¹:
 - > 50% share in Ambulatory Surgery Centers
 - 10-15% in Hospital Anesthesia Market
 - ~ 20% in Vital Signs Monitoring
- Large, established US and European direct sales and service organization dedicated to patient monitoring
- Recent approval of innovative, wireless monitoring solution, NetGuard

... More than the Sum of its Parts


Datascope PMB's direct sales and service team in US & Europe



Cross-selling opportunities, better distribution for Mindray's high price-to-performance products



Mindray's efficient component sourcing and China-based R&D




Enhanced ability to tailor / add functionality to Datascope products, better and faster response to customer needs



Pro Forma Operating Strategy

- Mindray's new US subsidiary, that will contain the Datascope PMB business, will be run by David Gibson, current President of Datascope PMB
- Mindray intends to keep substantially all of Datascope PMB employees in all areas, including sales & marketing, service, R&D and manufacturing
- Operating synergies will be achieved from manufacturing, SG&A and R&D









Clear Roadmap for Successful Integration



Value Contribution

Datascope's Leading Product Portfolio



Customer Segment	Product	Product Segment		
Emergency Room	1 Spectrum	Standalone Monitors		
	2 Passport 2			
	3 Trio			
Vital Signals	4 Accutorr Plus			
	5 Duo			
Operating Room	6 Spectrum OR Monitor			
	7 Gas Module SE			
	Anesthesia Systems			
9 AS-3000				
10 Artema				
Telemetry	11 Panorama		Central Monitoring System	

Value Contribution

Established Sales & Service Network



US

■ Direct Sales Model

- 86 sales and clinical support personnel in US
- Dedicated national account representatives
- Sales representatives
- Regional managers
- Clinical support specialists

■ Direct Service

- Direct field service
- Employees have been with Datascope for 15 years on average

International

■ Direct Sales Model with 17 sales reps and 4 clinical support specialists

- France
- Germany
- UK

■ Distributor Model

- Brazil
- Mexico
- HK
- Chile
- Caribbean
- Columbia

■ Direct Service

- UK
- Benelux
- Germany
- Egypt
- France
- HK

2007 Pro-Forma Operating Metrics

	Mindray	Datascope PMB	Mindray + Datascope PMB
Global Market Share ¹	4%	5%	9%
# Employees	3,705	442	4,147
R&D Staff	1,036	81	1,117
# FDA Approved Products	13	20	33
Revenue (\$mm)	305.8	161.3	467.1

Note:

1 2007 Frost & Sullivan research



Thank you!

Q&A